Pharmacopeia
Master Compare
Compare candidate-facing canonical Pharmacopeia fields side by side. Isolated AI-draft proposals are never included.
| Field |
EPHEDRINE
Cardiovascular · Cardiovascular · Level 3
|
METARAMINOL
Cardiovascular · Cardiovascular · Level 2
|
|---|---|---|
| Mechanism of action | direct and indirect sympathomimetic with alpha and beta activity |
through ↑TPR |
| Physiological effects | 1. CVS 2. Resp 3. CNS 4. GIT 5. GU 6. Metabolic |
CVS: CNS: Renal/GU Metabolic |
| Absorption | - Rapidly absorbed orally |
IV. BA 100% |
| Distribution | - Widely distributed and crosses BBB, placenta and breast milk |
limited data on pharmacokinetics |
| Metabolism | - Resistant to MAO and COMT. Hepatic metabolism with a major metabolite being active and may have central effects |
Hepatic |
| Excretion | - 50-90% excreted unchanged in urine. Urinary elimination is pH dependent (enhanced by acidic urine) |
Unknown |
| Half-life | Elimination T1/2 is 6 hours |
short |
| Adverse Effects Toxicity | Insomnia, anxiety, tremor, headache, dysrhythmias, nausea and vomiting, and chest pain |
Caution should be exercised in patients with pulmonary hypertension. May cause |
| Class Group | ADRENERGIC |
ADRENERGIC |
| Indications Uses | 1. Hypotension during surgery |
short term correction of BP in the setting of regional anaesthesia and off label for short term BP correction |
| Introduction | Synthetic direct and indirect sympathomimetic with alpha and beta activity |
synthetic noncatecholamine with both direct and indirect |
| Legacy Cicm Level | Level 2 |
Level 2 |
| Main Action | alpha and beta activity |
both direct and indirect |
| Presentation | - Clear colourless solution for injection (3-9mg slow injection, dose repeated ever 3-4 min) |
clear solution 10mg/mL in one mL vials and usually diluted to |
| Route And Dose | IV 3-6mg bolus |
IV boluses or infusion |